Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

BDTX

NASDAQ

Black Diamond Therapeutics (BDTX)

1.33 USD −4.32% vs prior close Nov 20, 2026
Black Diamond Therapeutics, Inc. price graph
64 sessions
2.5 1.0 24 Aug 20 Nov

The line runs 2.16 USD on 24 August through 1.33 USD on 20 November, on a scale from 1.0 to 2.5. Days the market did not trade hold the previous close, flat.

Market cap
76.4M USD
Revenue, year to Dec 2025
70.0M USD
EPS, diluted, year to Dec 2025
0.39 USD
52-week range
1.33 USD – 4.48 USD
Avg volume
52.8K

as of Nov 20, 2026

Have Black Diamond Therapeutics (BDTX) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, no Black Diamond Therapeutics insider bought or sold shares on the open market; all 2 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest Form 4 filing 18 Sep 2026

0buys
0sells
2other filings
Have Black Diamond Therapeutics (BDTX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
18 Sep 2026Raman PrakashDirectorAward6,80113K USD
18 Sep 2026Behbahani AliDirectorAward7,70715K USD

Which funds hold Black Diamond Therapeutics (BDTX)?

6 of the 45 institutional funds we track reported a Black Diamond Therapeutics position for the quarter ended 30 Sep 2026 — a combined 7.8M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Black Diamond Therapeutics (BDTX)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesHeld (±25%)1,652,1003.1M USD−15.8%
Marshall WaceAdded1,176,3572.2M USD+31.2%
AQR Capital ManagementNew position889,6331.7M USD
D. E. Shaw & Co.Added278,469525K USD+77.0%
Balyasny Asset ManagementTrimmed87,313165K USD−83.9%
Two Sigma InvestmentsHeld (±25%)40,60477K USD−3.3%

What has been filed or recorded for Black Diamond Therapeutics (BDTX)?

The filings we hold for Black Diamond Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Black Diamond Therapeutics (BDTX)?
And
26 Oct 2026Fails to deliverShares failed to deliver12,177 shares23K USD notional · 0.021% of shares out
22 Oct 2026Fails to deliverShares failed to deliver4,385 shares9K USD notional · 0.008% of shares out
14 Oct 2026Fails to deliverShares failed to deliver2,795 shares5K USD notional · 0.005% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.17 USD
30 Sep 2026FinancialsTotal assets115.6M USDat period end
30 Sep 2026FinancialsTotal equity88.1M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.17 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.16 USD
31 Dec 2025Annual reportFY 2025 reportedEPS 0.39 USD
31 Dec 2025FinancialsRevenue70.0M USDfiscal year
31 Dec 2025FinancialsNet income22.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS0.39 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.15 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.19 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS 0.98 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.27 USD

What do people ask about Black Diamond Therapeutics (BDTX)?

From live data
What did Black Diamond Therapeutics shares close at?1.33

Black Diamond Therapeutics closed at 1.33 USD on 20 Nov 2026, down 4.32% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Black Diamond Therapeutics’ market cap?76.4M

Black Diamond Therapeutics is worth 76.4M USD by market value as of 20 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Black Diamond Therapeutics’ revenue?70.0M

Black Diamond Therapeutics reported revenue of 70.0M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Black Diamond Therapeutics insiders bought or sold shares recently?2 filings

In the 90 days to 22 Nov 2026, no Black Diamond Therapeutics insider bought or sold shares on the open market; all 2 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4). See Insiders

Which funds own Black Diamond Therapeutics?6 of 45

6 of the 45 funds we track reported a Black Diamond Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Marshall Wace and AQR Capital Management. See Funds

When did Black Diamond Therapeutics last report earnings?−0.17

Black Diamond Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.17 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words